Electromechanical Reshaping of Porcine Eustachian Tube Cartilage Ex Vivo

Background and Objectives: The Eustachian tube cartilage (ETC) is the cartilaginous frame of the Eustachian tube (ET), which plays a pivotal role in its function. Existing treatments for ET dysfunction (ETD) are primarily based on mechanical deformation. Electromechanical reshaping (EMR) is a novel...

Full description

Saved in:
Bibliographic Details
Published inJournal of audiology & otology Vol. 29; no. 3; pp. 219 - 225
Main Authors Yoon, Byungwoo, Koo, Soo-Kweon, Baek, Moo-Jin, Lee, Il-Woo, Oh, Se-Joon, Kong, Soo-Keun
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Audiological Society and Korean Otological Society 01.07.2025
대한청각학회
Subjects
Online AccessGet full text
ISSN2384-1621
2384-1710
2384-1710
DOI10.7874/jao.2025.00157

Cover

More Information
Summary:Background and Objectives: The Eustachian tube cartilage (ETC) is the cartilaginous frame of the Eustachian tube (ET), which plays a pivotal role in its function. Existing treatments for ET dysfunction (ETD) are primarily based on mechanical deformation. Electromechanical reshaping (EMR) is a novel method used to reshape the cartilage into the desired form by applying an electric current using strategically placed needles for mechanical deformation. In this study, EMR was evaluated for its ability to reshape the ETC.Materials and Methods: A total of 84 ETCs were harvested from 42 post-mortem porcine crania and randomly divided into control and experimental (EMR) groups. To reshape the ETC, the control ETCs were subjected to a mechanical force, whereas the experimental group was subjected to the same force and current of 3, 4, or 5 V for 2 or 3 min. Changes in shape were assessed by measuring the contour angles using digital photographs.Results: In the analysis of the contour angle, ETC post-EMR for 2 min at ≥4 V demonstrated significant reshaping relative to the control group (p<0.05).Conclusions: EMR can be used to reshape the ETCs ex vivo. Future experiments with well-designed ex vivo and in vivo conditions are required to develop novel therapeutic options for ETD.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2384-1621
2384-1710
2384-1710
DOI:10.7874/jao.2025.00157